Patent US4414150A successfully refreshed from Google Patents.
US4414150A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Hybrid human leukocyte interferons
Assignee: Hoffmann La Roche Inc
•
Filing: 1981-02-23
•
Granted: 1983-11-08
•
Expires: 2001-02-23
Abstract
Abstract Disclosed herein are methods and means of microbially preparing novel human hybrid leukocyte interferons, useful in the treatment of viral and neoplastic diseases, by DNA recombination of parental interferon genes, taking advantage of common restriction endonuclease cleavage sites therein and in carrier expression plasmids.
Inventors
- 👤 David V. Goeddel
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-25 16:13
CPC Classifications
C; C12; C12N; C12N15/00; C12N15/09; C12N15/63; C12N15/70; C12N15/71; C07; C07K; C07K14/00; C07K14/435; C07K14/52; C07K14/555; C07K14/56; A; A61; A61K; A61K38/00; Y; Y10; Y10S; Y10S435/00; Y10S435/811; Y10S530/00; Y10S530/808; Y10S930/00; Y10S930/01; Y10S930/14; Y10S930/142
Claims Analysis
Total Claims: 8
Claim 1
Independent Claim
72 words
An antiviral composition of matter comprising a polypeptide of 165-166 amino acids, optionally having an additional methionine attached to the ordinarily first amino acid at the N-terminus, the amino acid sequence of said polypeptide comprising, in sequence, discrete sub-sequences corresponding in amino acid identity and number to sub-sequences of different, naturally occurring leukocyte interferons, the amino acid sequence of said polypeptide differing from the amino acid sequence of naturally occurring leukocyte interferons.
Claim 2
Dependent Claim
72 words
An antiviral composition of matter comprising a polypeptide of 165-166 amino acids, optionally having an additional methionine attached to the ordinarily first amino acid at the N-terminus, the amino acid sequence of said polypeptide comprising, in sequence, discrete sub-sequences corresponding in amino acid identity and number to sub-sequences of different, naturally occurring leukocyte interferons, the amino acid sequence of said polypeptide differing from the amino acid sequence of naturally occurring leukocyte interferons.
Claim 3
Dependent Claim
61 words
An antiviral composition of matter according to claim 1 comprising a polypeptide of 166 amino acids, the N-terminal portion of said polypeptide consisting essentially of amino acids 1-92 of LeIF-D and the carboxy terminal portion of said polypeptide consisting essentially of amino acids 92-165 of LeIF-A, the carboxy terminus of said polypeptide corresponding essentially to the carboxy terminus of LeIF A.
Claim 4
Dependent Claim
62 words
An antiviral composition of matter according to claim 1 comprising a polypeptide of 165 amino acids, the N-terminal portion of said polypeptide consisting essentially of amino acids 1-91 of LeIF A and the carboxy terminal portion of said polypeptide consisting essentially of amino acids 93-166 of LeIF-D, the carboxy terminus of said polypeptide corresponding essentially to the carboxy terminus of LeIF D.
Claim 5
Dependent Claim
63 words
An antiviral composition of matter according to claim 1 comprising a polypeptide of 166 amino acids, the N-terminal portion of said polypeptide consisting essentially of amino acids 1-63 of LeIF D and the carboxy terminal portion of said polypeptide consisting essentially of amino acids 63-165 of LeIF A, the carboxy terminus of said polypeptide corresponding essentially to the carboxy terminus of LeIF A.
Claim 6
Dependent Claim
62 words
An antiviral composition of matter according to claim 1 comprising a polypeptide of 165 amino acids, the N-terminal portion of said polypeptide consisting essentially of amino acids 1-62 of LeIF A, the carboxy terminal portion of said polypeptide consisting essentially of amino acids 64-166 of LeIF D, the carboxy terminus of said polypeptide corresponding essentially to the carboxy terminus of LeIF D.
Claim 7
Dependent Claim
63 words
An antiviral composition of matter according to claim 1 comprising a polypeptide of 165 amino acids, the N-terminal portion of said polypeptide consisting essentially of amino acids 1-91 of LeIF A and the carboxy terminal portion of said polypeptide consisting essentially of amino acids 93-166 of LeIF B, the carboxy terminus of said polypeptide corresponding essentially to the carboxy terminus of LeIF B.
Claim 8
Dependent Claim
62 words
An antiviral composition of matter according to claim 1 comprising a polypeptide of 165 amino acids, the N-terminal portion of said polypeptide consisting essentially of amino acids 1-91 of LeIF A, the carboxy terminal portion of said polypeptide consisting essentially of amino acids 93-166 of LeIF F, the carboxy terminus of said polypeptide corresponding essentially to the carboxy terminus of LeIF F.
References Cited (Backward Citations)
US4262090A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1986-11-07 | 1987-05-09 | 1987-11-08 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1990-11-07 | 1991-05-09 | 1991-11-08 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1994-11-07 | 1995-05-09 | 1995-11-08 | $7700.00 | Window Closed / Lapsed |